Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...

Fintel reports that on April 29, 2025, TD Cowen downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Buy to Hold.

Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

Drugmaker Novo Nordisk announced Tuesday that Wegovy will be available through telehealth providers. The providers -- Hims & ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Novo Nordisk has sought strength in numbers in the battle for telehealth obesity drug sales in the US, enlisting the aid of ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.

Wegovy, the popular weight-loss drug from Novo Nordisk, will be available through several leading telehealth providers, ...

Thatch, the leading platform for modern, flexible health benefits, today announced the launch of the Thatch Marketplace, a curated ecosystem of health and wellness services that employees can access ...